Emavusertib (CA-4948)

About Curis

Curis is a clinical-stage oncology company dedicated to developing novel therapies that slow or prevent cancer progression. Its lead asset, Emavusertib, is an oral IRAK4 inhibitor in clinical trials for IRAK4-driven leukemias and lymphomas. The company also benefits from a collaboration with Roche/Genentech on the commercialized drug Erivedge for advanced basal cell carcinoma, providing non-dilutive funding. Curis is strategically focused on hematologic malignancies and immune checkpoint modulation.

About Curis

Curis is a clinical-stage oncology company dedicated to developing novel therapies that slow or prevent cancer progression. Its lead asset, Emavusertib, is an oral IRAK4 inhibitor in clinical trials for IRAK4-driven leukemias and lymphomas. The company also benefits from a collaboration with Roche/Genentech on the commercialized drug Erivedge for advanced basal cell carcinoma, providing non-dilutive funding. Curis is strategically focused on hematologic malignancies and immune checkpoint modulation.

Therapeutic Areas